Journal article

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation

Kai Wang, Graham S Baldwin, Mehrdad Nikfarjam, Hong He

WORLD JOURNAL OF GASTROENTEROLOGY | BAISHIDENG PUBLISHING GROUP INC | Published : 2018

Abstract

Pancreatic cancer is one of the most aggressive and lethal malignancies worldwide, with a very poor prognosis and a five-year survival rate less than 8%. This dismal outcome is largely due to delayed diagnosis, early distant dissemination and resistance to conventional chemo-therapies. Kras mutation is a well-defined hallmark of pancreatic cancer, with over 95% of cases harbouring Kras mutations that give rise to constitutively active forms of Kras. As important down-stream effectors of Kras, p21-activated kinases (PAKs) are involved in regulating cell proliferation, apoptosis, invasion/migration and chemo-resistance. Immunotherapy is now emerging as a promising treatment modality in the era..

View full abstract